Engineered RBCs for Antigen-Specific Tolerance
Type 1 Diabetes
Key Facts
About Portal Biotechnologies
Portal Biotechnologies is a private, platform technology company pioneering a novel physical method for intracellular delivery called 'Cell Squeeze®'. This technology enables the delivery of a wide range of cargo (proteins, nucleic acids, CRISPR components) into virtually any cell type, including hard-to-transfect primary immune cells, with high efficiency and viability. The company has rapidly gained traction with over 50 biopharma and academic partners, secured significant non-dilutive funding from DARPA, and completed an oversubscribed seed round. Portal's strategy involves selling research instruments (Gateway, Galaxy) to drive platform adoption while developing its own therapeutic programs and partnerships in cell therapy and immuno-oncology.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |